CCCC

C4 Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · c4therapeutics.com

$3.04

Pre-mkt $3.03 -0.16%

Mkt Cap $251.4M

52w Low $1.21 69.9% of range 52w High $3.82

50d MA $2.79 200d MA $2.45

P/E (TTM) -2.3x

EV/EBITDA -1.4x

P/B 0.9x

Debt/Equity 0.2x

ROE -40.9%

P/FCF -1.6x

RSI (14) —

ATR (14) —

Beta 2.86

50d MA $2.79

200d MA $2.45

Avg Volume 2.6M

About

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-0.31	-0.18	+41.9%	2.78	+0.0%	-2.9%	+14.0%	+6.1%	+11.2%	+9.0%	—
Nov 6, 2025	AMC	-0.47	-0.44	+6.4%	2.38	-1.3%	-1.7%	-1.7%	+4.2%	+4.2%	+2.9%	—
Aug 7, 2025	AMC	-0.38	-0.37	+2.6%	2.58	+3.5%	-3.1%	-6.2%	-13.2%	-9.7%	-8.9%	—
May 7, 2025	AMC	-0.48	-0.37	+22.9%	1.50	+2.0%	+2.7%	-2.0%	+5.3%	+0.0%	-8.7%	—
Feb 27, 2025	AMC	-0.44	-0.49	-11.4%	2.60	-0.4%	+4.2%	-7.7%	-8.5%	-6.5%	-9.2%	—
Oct 31, 2024	AMC	-0.40	-0.35	+12.5%	5.33	+4.9%	+5.3%	+21.0%	+14.3%	+12.0%	+13.3%	—
Aug 1, 2024	AMC	-0.37	-0.26	+29.7%	6.68	-5.2%	-3.9%	-11.8%	-10.2%	-13.3%	-13.3%	—
May 8, 2024	AMC	-0.41	-0.41	+0.0%	6.45	+1.6%	+5.4%	-4.5%	-4.3%	-7.0%	-5.3%	—
Feb 22, 2024	AMC	-0.67	-0.68	-1.5%	8.80	+1.5%	+2.2%	+8.1%	+10.8%	+24.4%	+24.8%	—
Nov 1, 2023	AMC	-0.65	-0.55	+15.4%	1.32	-2.3%	+6.1%	+18.2%	+37.1%	+41.7%	+40.2%	—
Aug 8, 2023	AMC	-0.74	-0.73	+1.4%	3.51	+0.9%	-1.4%	-2.3%	-2.8%	-3.7%	-3.7%	—
May 4, 2023	AMC	-0.78	-0.71	+9.0%	3.23	+5.3%	+1.9%	+0.0%	+2.8%	+4.6%	+4.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 27	Barclays	Maintains	Overweight → Overweight	—	$2.78	$2.78	+0.0%	-2.9%	+14.0%	+6.1%	+11.2%	+9.0%
Feb 23	Brookline Capital	Maintains	Buy → Buy	—	$2.16	$2.15	-0.5%	+6.5%	+10.6%	+28.2%	+28.7%	+25.0%
Dec 17	Barclays	Maintains	Overweight → Overweight	—	$2.26	$2.30	+1.8%	-9.3%	-11.1%	-10.2%	-7.5%	-10.6%
Sep 23	Wells Fargo	Maintains	Overweight → Overweight	—	$2.61	$2.80	+7.3%	-0.8%	-7.3%	-16.1%	-14.6%	-14.6%
Sep 23	Barclays	Maintains	Overweight → Overweight	—	$2.61	$2.80	+7.3%	-0.8%	-7.3%	-16.1%	-14.6%	-14.6%
Sep 22	Stephens & Co.	Maintains	Overweight → Overweight	—	$3.16	$3.30	+4.4%	-17.4%	-18.0%	-23.4%	-30.7%	-29.4%
Sep 15	Stephens & Co.	Upgrade	Equal Weight → Overweight	—	$2.66	$2.81	+5.6%	+34.2%	+28.2%	+27.1%	+24.8%	+18.8%
Dec 19	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$3.66	$4.00	+9.3%	+5.2%	+7.9%	+10.9%	+5.7%	+9.3%
Aug 6	BMO Capital	Maintains	Outperform → Outperform	—	$5.89	$5.93	+0.7%	+1.9%	-1.7%	-1.7%	-8.3%	-2.9%
May 9	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$6.45	$6.55	+1.6%	+5.4%	-4.5%	-4.3%	-7.0%	-5.3%
May 9	Stifel	Maintains	Buy → Buy	—	$6.45	$6.55	+1.6%	+5.4%	-4.5%	-4.3%	-7.0%	-5.3%
Feb 26	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$8.99	$9.00	+0.1%	+5.8%	+8.5%	+21.8%	+22.1%	+22.2%
Feb 23	Stifel	Maintains	Buy → Buy	—	$8.80	$8.93	+1.5%	+2.2%	+8.1%	+10.8%	+24.4%	+24.8%
Jan 29	JP Morgan	Upgrade	Underweight → Neutral	—	$5.47	$5.60	+2.4%	+15.7%	+9.9%	+13.0%	+5.7%	-1.8%
Dec 13	Stifel	Upgrade	Hold → Buy	—	$2.34	$3.18	+35.9%	+135.5%	+114.1%	+111.5%	+96.2%	+94.0%
Nov 6	Morgan Stanley	Upgrade	Underweight → Equal Weight	—	$1.56	$1.53	-1.9%	+16.0%	+19.9%	+18.6%	+12.8%	+10.3%
Nov 3	BMO Capital	Maintains	Outperform → Outperform	—	$1.40	$1.42	+1.4%	+11.4%	+29.3%	+33.6%	+32.1%	+25.7%
Nov 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.32	$1.29	-2.3%	+6.1%	+18.2%	+37.1%	+41.7%	+40.2%
Oct 9	BofA Securities	Maintains	Neutral → Neutral	—	$1.71	$1.73	+1.2%	-5.3%	+10.5%	+11.1%	+7.6%	+16.4%
Aug 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.51	$3.54	+0.9%	-1.4%	-2.3%	-2.8%	-3.7%	-3.7%
May 30	Evercore ISI	Maintains	Outperform → Outperform	—	$3.08	$3.19	+3.6%	+8.8%	+10.1%	+9.1%	+10.1%	+11.0%
May 12	Morgan Stanley	Maintains	Underweight → Underweight	—	$3.37	$3.37	+0.0%	-3.3%	-0.9%	-8.0%	-6.8%	-5.6%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.29	$3.32	+0.9%	-1.8%	+0.9%	+2.7%	+2.4%	-0.9%
Mar 28	BofA Securities	Maintains	Neutral → Neutral	—	$3.46	$3.42	-1.2%	-3.8%	-1.7%	-10.4%	-9.2%	-7.5%
Feb 27	Morgan Stanley	Maintains	Underweight → Underweight	—	$5.33	$5.36	+0.6%	+0.2%	-1.1%	-5.3%	-4.9%	-3.4%
Feb 24	JP Morgan	Downgrade	Neutral → Underweight	—	$6.02	$5.34	-11.3%	-11.5%	-11.3%	-12.5%	-16.1%	-15.8%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.02	$5.34	-11.3%	-11.5%	-11.3%	-12.5%	-16.1%	-15.8%
Jan 3	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$5.90	$5.92	+0.3%	+8.1%	+12.5%	+10.3%	+13.9%	+21.2%
Nov 8	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$8.86	$8.89	+0.3%	+2.5%	-12.0%	-0.8%	+2.0%	+2.8%
Nov 4	JP Morgan	Downgrade	Overweight → Neutral	—	$9.90	$9.31	-6.0%	-10.0%	-10.5%	-8.3%	-21.2%	-11.2%
Oct 11	Morgan Stanley	Maintains	Underweight → Underweight	—	$7.73	$7.31	-5.4%	-1.9%	-0.1%	+7.0%	+3.0%	+11.0%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.43	$8.18	-3.0%	-8.1%	-12.2%	-23.7%	-20.0%	-15.2%
Apr 28	Credit Suisse	Maintains	Underperform → Underperform	—	$8.85	$8.58	-3.1%	+0.3%	-3.2%	+5.9%	+1.9%	+3.6%
Apr 18	UBS	Maintains	Buy → Buy	—	$8.95	$8.86	-1.0%	+1.8%	+5.4%	+0.7%	-1.3%	+2.5%
Apr 11	BMO Capital	Maintains	Outperform → Outperform	—	$11.32	$10.19	-10.0%	-29.2%	-22.6%	-17.4%	-20.9%	-19.5%
Mar 10	JP Morgan	Maintains	Overweight → Overweight	—	$24.21	$25.04	+3.4%	-0.6%	-3.5%	-12.1%	-11.2%	-6.5%
Feb 10	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$24.51	$23.57	-3.8%	-3.0%	-3.5%	-7.3%	-2.5%	-5.0%
Nov 23	BofA Securities	Maintains	Buy → Buy	—	$37.04	$38.83	+4.8%	+3.2%	+2.1%	-1.1%	-2.9%	+0.2%
Oct 14	SVB Leerink	Maintains	Outperform → Outperform	—	$41.58	$41.94	+0.9%	+6.4%	+5.6%	+3.3%	+6.9%	+3.0%
Sep 30	Stifel	Maintains	Hold → Hold	—	$47.97	$46.61	-2.8%	-6.9%	-4.2%	-6.2%	-6.9%	-6.8%
Jun 24	Brookline Capital	Maintains	Buy → Buy	—	$37.76	$38.47	+1.9%	-1.3%	-0.1%	-1.6%	-1.7%	+0.2%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.15	$40.00	+4.8%	+2.3%	+8.7%	+6.3%	+10.1%	+10.1%
Mar 31	BMO Capital	Maintains	Outperform → Outperform	—	$32.90	$33.00	+0.3%	+12.4%	+17.4%	+14.0%	+14.0%	+9.9%
Oct 27	BMO Capital	Maintains	Outperform → Outperform	—	$26.23	$27.06	+3.2%	-2.0%	-4.4%	-4.3%	-5.6%	-5.7%

Recent Filings

8-K · 5.03 ! Medium

Unknown — 8-K 5.03: Amendment to Articles / Bylaws

CCCC amended its bylaws regarding officer duties and responsibilities, likely clarifying governance procedures; investors should monitor if this signals leadership changes or shifts in corporate structure affecting decision-making authority.

Apr 10

8-K · 1.01 !! High

Unknown — 8-K 1.01: License Agreement

CCCC secured a major pharmaceutical partnership with industry giant Roche, potentially validating its pipeline and providing near-term revenue through upfront payments and milestone fees.

Apr 9

8-K

C4 Therapeutics, Inc. -- 8-K Filing

C4 Therapeutics extended its cash runway past key milestones while advancing its lead drug cemsidomide through a differentiated regulatory pathway, demonstrating best-in-class potential in targeted protein degradation.

Feb 26

Data updated apr 25, 2026 12:15am · Source: massive.com